Table 6.
Ongoing clinical trials of therapies affecting DNA damage repair pathways that include patients with pancreatic cancer
| Trial | Design | Patients | Treatment | Status |
| NCT02950064 | Phase I trial, open-label | BRCA-mutated pancreatic, ovarian, triple-negative breast or prostate cancers or solid tumours with other DDR mutations | BTP-114, a novel platinum product | Active, not recruiting |
| NCT01489865 | Phase I/II trial, single arm | PDAC with BRCA mutation or personal or family history of hereditary breast or ovarian cancer | ABT-888 (a new PARP inhibitor) with mFOLFOX6 | Active, not recruiting |
| NCT01585805 | Phase II, open-label, randomised | Metastatic or locally advanced BRCA-mutated PDAC | Veliparib alone vs gemcitabine/cisplatin vs veliparib and gemcitabine/cisplatin | Active, not recruiting |
| NCT02498613 | Phase II trial, single arm | Advanced solid tumours with failure to at least one line of standard systemic treatment | Olaparib+cediranib (anti-VEGF) | Recruiting |
| NCT03162627 | Phase I/II | Refractory advanced cancer | Olaparib+selumetinib (anti-MEK) | Recruiting |
| NCT03404960 | Phase Ib/II, open-label, randomised | Metastatic or locally advanced PDAC, with 16 weeks of platinum-based treatment without progression | Niraparib+nivolumab or ipilimumab | Recruiting |
| NCT02630199 | Phase I, open-label | Advanced, refractory cancer | Paclitaxel and AZD6738 (ATR inhibitor) | Recruiting |
| NCT02223923 | Phase I, single group | Solid tumour refractory to conventional treatment | AZD6738 (ATR inhibitor) with radiotherapy | Recruiting |
| NCT03669601 | Phase I, non-randomised | Locally advanced or metastatic solid tumour that has progressed on standard therapy | AZD6738 and gemcitabine | Recruiting |
| NCT02264678 | Phase I, two-part, open-label | Solid malignant tumour that is not considered appropriate for further standard treatment | AZD6738 with different drugs, including carboplatin and olaparib | Recruiting |
| NCT03682289 | Phase II | Locally advanced or metastatic solid tumour malignancy, including any pancreatic cancers | AZD6738 alone or in combination with olaparib | Recruiting |
| NCT02576444 | Phase II | Metastatic progressive cancer | Patients with HRD will be treated with olaparib and AZD6738 | Active, not recruiting |
| NCT02723864 | Phase I, single group | Metastatic cancer with previous fail to survival prolonging therapies | Veliparib+cisplatin+VX-970 (ATR inhibitor) | Recruiting |
| NCT02595931 | Phase I, single group | Metastatic or unresectable malignancy that is refractory to standard therapy or for which no standard therapy exists and where irinotecan is deemed a reasonable treatment option | VX-970 and irinotecan | Recruiting |
| NCT02588105 | Phase I | Locally advanced/metastatic cancer that is refractory or resistant to standard therapy, or have no effective standard | AZD0156+olaparib, AZD0156+irinotecan/FOLFIRI | Active, not recruiting |
| NCT02194829 | Phase I | A phase I and randomised phase II study of nab-paclitaxel/gemcitabine with or without AZD1775 for treatment of metastatic adenocarcinoma of the pancreas | Nab-paclitaxel/gemcitabine Nab-paclitaxel/gemcitabine+AZD1775 |
Active, not recruiting |
FOLFIRI, folinic acid, fluouracil, irinotecan; FOLFOX, folinic acid, fluouracil, oxaliplatin; nab, nanosized albumin-bound; PDAC, pancreatic ductal adenocarcinoma.